LazaTrades

Wow! We just got recognized by activ8insights.com/ . Some of the biggest short-selling research firms are competing for the top spots, and I made the Top 5!

My verified year-over-year performance, audited by the Active8Insight team, came in at 71%.

The best part? That performance comes entirely from the free short reports I've shared and that anyone can follow us here https://redflagresearch.substack.com/

Also what is cool about it is you can see, looking at red dot at each report, when it was published and what was live price

Hi all! Worth 2 min of reading;
Welcome to RedFlag Research https://redflagresearch.substack.com

Over two years,we specialize in uncovering dilution risks, toxic financings, promotional activity, and structural red flags in small-cap stocks before the market fully prices them in.

Recently, we published our $CODX report before the decline, highlighting:

• A large PIPE financing
• Deep in-the-money warrants
• An S-3 resale registration unlocking millions of shares
• Multiple layers of future dilution pressure

Based on our analysis, we established a short position at approximately $12.20 per share with several thousand shares and published a downside target of $6–$8. Current price is at $8.6 while you reading this, 75% profit locked already.

As the stock moved lower, our thesis played out as anticipated, demonstrating the type of filing-driven opportunities we seek to identify before they become widely recognized by the market.

Follow RedFlag Research for deep-dive investigations, SEC filing analysis, and high-conviction small-cap research.

We already did a short report on this back in 2025!

HOTH → now RKTO is a full pivot into AI/space after years of biotech dilution and early-stage trial progress.

Check full free report below:
https://redflagresearch.substack.com/p/2025-redflag-research-hoth-12-patients?utm_source=publication-search

Follow up report tomorrow! Looking for potential SHORT.

[2025] RedFlag Research: $HOTH: 12 Patients, 150 Promised— Fast Track FDA ; Will Your Shares Disappear in the Next Funding Round? Dilution, regulatory gambit, and silent insiders: why this ‘Fast-Tracked’ biotech may be more flash than cure.

Ok, fundamentals here are weak. There was actually SOF Week in Tampa Florida, where a lot of companies go to showcase their products, and $VUZI had its own booth, so we went to check it out in person.

As mentioned in the report, the short target was in the $5–6 range. I shorted at $5.40 and covered at $4.60.

Full story here:
https://redflagresearch.substack.com/p/vuzix-vuzi-another-old-promo-story

Follow free newsletter

RedFlagHunter | Substack $Reports. I dig deep into filings and fundamentals to uncover red flags and weak narratives-and share the journey along the way. Click to read RedFlagHunter, by Red Flag Research, a Substack publication with hundreds of subscribers.

Follow me on Insta! https://www.instagram.com/laza_trades/
Im traveling at the moment! Miami to Turkey, doing some investigation on the stock $VUZI.

Lazar Marjanovic (@laza_trades) • Instagram photos and videos 996 Followers, 938 Following, 292 Posts - See Instagram photos and videos from Lazar Marjanovic ()